Harold Bernstein, President, R&D & Chief Medical Officer of Maze Therapeutics (NASDAQ: MAZE), exercised and sold 30,000 shares on March 10, 2026, realizing approximately $1.51 million at a weighted-average price of $50.45 per share. This transaction, part of a Rule 10b5-1 trading plan, eliminated Bernstein’s direct ownership in the stock, although he retains 267,407 stock options.
Despite Bernstein’s sale, which typically raises eyebrows among investors, analysts suggest it should not be a cause for concern. Maze Therapeutics has seen a consistent upward trajectory, with its stock price increasing for 11 consecutive months as of March 21, 2026. The company is advancing in clinical trials for its lead candidates targeting renal and metabolic diseases, and remains a strong buy among Wall Street analysts ahead of its upcoming Q4 earnings report scheduled for April 6.
Investors should remain cautious, however, as the stock’s bullish momentum could lead to a brief drawdown. With Bernstein’s recent sale and the impending earnings report, market participants may want to reassess their positions in Maze Therapeutics.
Source: nasdaq.com